Bluthgen, M.V.

Früh, M.

Gautschi, O.

Mazieres, J.

Milia, J.

Peters, S.

Schuler, M.

Smit, E.F.

Wolf, J.

Zalcman, G.

RERO DOC Digital Library

98O PR TARGETED THERAPY FOR BRAF-MUTANT LUNG CANCER:RESULTS FROM THE EUROPEAN EURAF COHORT STUDYO. Gautschi1, M.V. Bluthgen2, E.F. Smit3, J. Wolf4, M. Früh5, S. Peters6,M. Schuler7, G. Zalcman8, J. Milia9, J. Mazieres91Medical Oncology, Luzerner Kantonsspital, Lucerne, Switzerland2IOT Institut d’Oncologie Thoracique, Gustave Roussy, Paris, France3Dept. of Pulmonary Diseases, Vrije University Medical Centre (VUMC),Amsterdam, Netherlands4CIO Center for Integrated Oncology, University of Cologne, Cologne, Germany5Hematology/Oncology, Kantonsspital St. Gallen, St. Gallen, Switzerland6Oncology, Centre Hospitalier Universitaire Vaudois – CHUV, Lausanne,Switzerland7Innere Klinik (Tumorforschung), Westdeutsches Tumorzentrum Essen, Essen,Germany8Service de Pneumologie, CHU de Caen, Caen, France9Thoracic Oncology, CHU Toulouse, Hôpital de Larrey, Toulouse, FranceAim: About 2% of lung adenocarcinomas have BRAF mutations. The BRAF inhibitors(BRAFi) vemurafenib (V) and dabrafenib (D) had promising activity in first clinicaltrials, but only few centers participated, and many patients (pts) were not enrolled.Our aim was to study the clinical course of those pts.Methods:We conducted a retrospective ulticentre cohort study in Europe of pts withadvanced BRAF-mutant lung cancer treated outside of a clinical trial. Data wereanonymized and centrally assessed for age, gender, smoking, histology, stage, localmolecular diagnostic results, systemic therapies, and survival. Best response waslocally assessed by RECIST1.1. This academic study was conducted without industrysupport.Results: By December 2014, 35 pts received individual BRAFi therapy in 17participating centers. Median age at diagnosis was 64 years (range 43-85), 18 (51%)male, 16 (46%) current or former smoker. All 35 (100%) pts had lungadenocarcinoma histology, 29 (83%) had BRAF V600E, 6 (17%) had other BRAFmutations, 1 (3%) also had a concomitant KRAS mutation. 30 (86%) pts had priorchemotherapy, 5 (14%) had frontline BRAFi therapy. BRAFi used were V (28 pts), D(10 pts), and sorafenib (S, 1 pt). 31 (89%) pts received 1 BRAFi (24 V, 7 D) and 4 ptsreceived 2 (V followed by D in 3 pts, S followed by V in 1 pt). Best response byRECIST was available for 36 (92%) of 39 BRAFi therapies: 2 (6%) CR, 17 (47%) PR,13 (36%) SD, and 4 (11%) PD; overall response rate (ORR) was 53% (95%CI:35-70%). Among the 6 pts with non-V600E, 1 (17%) achieved a PR. No unexpectedtoxicities were reported. Further results including updated survival will be presentedat the meeting.Conclusions: These results support BRAF testing in advanced lungadenocarcinoma, and BRAFi therapy in patients with V600E. Further studiesare warranted to evaluate combination therapies and potential drug resistancemechanisms.Disclosure:M. Schuler: Advisory role with compensation from Novartis and GSK.Allother authors have declared no conflicts of interest.© European Society for Medical Oncology 2015. Published by Oxford University Press on behalf of the European Lung Cancer Conference (ELCC) 2015 organisers.All rights reserved. For permissions, please email: journals.permissions@oup.com.abstractsdoi:10.1093/annonc/mdv128.7Annals of Oncology 26 (Supplement 1): i57–i61, 2015

98O_PRTARGETED THERAPY FOR BRAF-MUTANT LUNG CANCER: RESULTS FROM THE EUROPEAN EURAF COHORT STUDY

http://doc.rero.ch/record/299154/files/mdv128.07.pdf

98O_PRTARGETED THERAPY FOR BRAF-MUTANT LUNG CANCER: RESULTS FROM THE EUROPEAN EURAF COHORT STUDY

Abstract

Similar works

Full text

Available Versions

RERO DOC Digital Library